chronic hepatitis B
Conditions
Interventions
therapy group:Medical treatment+Oral tenofovir amibufenamide 1 tablet daily
Sponsors
Linyi People's Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age 65 and above; 2. Patients with chronic hepatitis B who meet the diagnostic criteria of "Guidelines for the Prevention and Treatment of Chronic Hepatitis B" (2019 Edition); 3. HBV DNA can be detected; 4. Patients who agree to participate in this clinical trial and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Under the age of 65; 2. Patients co-infected with human immunodeficiency virus or requiring long-term immunosuppressive therapy; 3. Those who plan to undergo an organ transplant or have received an organ transplant; 4. Patients with hepatocellular carcinoma or other malignant tumors; 5. Patients with other liver diseases, including viral hepatitis C, alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease, etc.; 6. Creatinine clearance less than 50ml/min before enrollment; 7. Child-Pugh score greater than 9 (Grade C); 8. Lactose intolerant; 9. History of alcohol or drug abuse within the last 1 year; 10. Male subject's spouse has a pregnancy plan in the next 2 years; 11. Patients who have participated in clinical trials of other drugs within the last 3 months; 12. Patients who cannot adhere to or are unwilling to participate in the study, or those who are deemed unsuitable by the investigator to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;Biochemical tests;HBsAg;HBeAg;Bone mineral density; | — |
Countries
China
Contacts
Public ContactFeng Gao
Linyi People's Hospital
Outcome results
None listed